Core Insights - Dogwood Therapeutics has achieved over 50% enrollment in its HALT-CINP Phase 2b trial for chemotherapy-induced neuropathic pain, with top line results expected in Q3 2026 [1][4] - The low early termination rate of 4.3% among the first 116 patients indicates that the Halneuron treatment is well tolerated [1][2] - If successful, Halneuron could become the first approved therapy for chemotherapy-induced neuropathic pain, addressing a significant unmet medical need [2] Enrollment and Study Design - The HALT-CINP trial is designed to provide over 80% statistical power to detect treatment differences between Halneuron and placebo upon unblinding in Q3 2026 [3] - The trial involves 8 subcutaneous doses of Halneuron or placebo over 14 days, with a total follow-up of 28 days to assess safety and effectiveness [4] Interim Results - An interim analysis of 97 patients showed that those treated with Halneuron demonstrated significant pain improvement compared to placebo, with an average duration of chemotherapy-induced neuropathic pain of 5 years [2] - The overall dropout rate of approximately 4.0% is significantly lower than typical rates observed in studies of other FDA-approved chronic pain medications [2] Company Overview - Dogwood Therapeutics is focused on developing new medicines for pain and neuropathic disorders, with Halneuron as its lead product candidate currently in Phase 2b development [5] - Halneuron has received fast track designation from the FDA for treating chemotherapy-induced neuropathic pain and is a non-opioid analgesic targeting voltage-gated sodium channels [5] Future Developments - The company is also developing SP16 IV, which has potential applications in treating neuropathy and repairing nerve damage following chemotherapy, with funding from the National Cancer Institute for its upcoming Phase 1b trial [5]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026